Technical Analysis for TCRX - TScan Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week High | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | -0.67% | |
| New 52 Week Closing High | Bullish | -0.67% | |
| Wide Bands | Range Expansion | -0.67% | |
| 20 DMA Support | Bullish | 11.49% | |
| Wide Bands | Range Expansion | 11.49% | |
| MACD Bearish Signal Line Cross | Bearish | 15.52% | |
| 20 DMA Support | Bullish | 15.52% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 14 hours ago |
| Up 3% | about 17 hours ago |
| Down 1% | about 17 hours ago |
| 2x Volume Pace | about 17 hours ago |
| 1.5x Volume Pace | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.36 |
| 52 Week Low | 1.94 |
| Average Volume | 210,139 |
| 200-Day Moving Average | 5.14 |
| 50-Day Moving Average | 7.54 |
| 20-Day Moving Average | 7.91 |
| 10-Day Moving Average | 8.42 |
| Average True Range | 0.58 |
| RSI (14) | 64.03 |
| ADX | 21.68 |
| +DI | 33.54 |
| -DI | 19.41 |
| Chandelier Exit (Long, 3 ATRs) | 7.63 |
| Chandelier Exit (Short, 3 ATRs) | 8.31 |
| Upper Bollinger Bands | 9.29 |
| Lower Bollinger Band | 6.54 |
| Percent B (%b) | 0.87 |
| BandWidth | 34.74 |
| MACD Line | 0.33 |
| MACD Signal Line | 0.27 |
| MACD Histogram | 0.0575 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.68 | ||||
| Resistance 3 (R3) | 9.74 | 9.55 | 9.56 | ||
| Resistance 2 (R2) | 9.55 | 9.36 | 9.52 | 9.51 | |
| Resistance 1 (R1) | 9.24 | 9.24 | 9.15 | 9.18 | 9.47 |
| Pivot Point | 9.05 | 9.05 | 9.00 | 9.02 | 9.05 |
| Support 1 (S1) | 8.74 | 8.86 | 8.65 | 8.68 | 8.39 |
| Support 2 (S2) | 8.55 | 8.74 | 8.52 | 8.35 | |
| Support 3 (S3) | 8.24 | 8.55 | 8.31 | ||
| Support 4 (S4) | 8.18 |
